95 related articles for article (PubMed ID: 1581892)
1. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo.
Genne P; Dimanche-Boitrel MT; Mauvernay RY; Gutierrez G; Duchamp O; Petit JM; Martin F; Chauffert B
Cancer Res; 1992 May; 52(10):2797-801. PubMed ID: 1581892
[TBL] [Abstract][Full Text] [Related]
2. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance.
Genne P; Duchamp O; Solary E; Magnette J; Belon JP; Chauffert B
Anticancer Drug Des; 1995 Mar; 10(2):103-18. PubMed ID: 7710633
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.
Genne P; Duchamp O; Solary E; Pinard D; Belon JP; Dimanche-Boitrel MT; Chauffert B
Leukemia; 1994 Jan; 8(1):160-4. PubMed ID: 8289482
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance.
Genne P; Coudert B; Pelletier H; Girardot C; Martin F; Chauffert B
Anticancer Res; 1989; 9(6):1655-9. PubMed ID: 2627117
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion.
Pelletier H; Millot JM; Chauffert B; Manfait M; Genne P; Martin F
Cancer Res; 1990 Oct; 50(20):6626-31. PubMed ID: 2208125
[TBL] [Abstract][Full Text] [Related]
6. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induced by doxorubicin and cinchonine in P388 multidrug-resistant cells.
Furusawa S; Nakano S; Wu J; Sakaguchi S; Takayanagi M; Sasaki KI; Satoh S
J Pharm Pharmacol; 2001 Jul; 53(7):1029-39. PubMed ID: 11480538
[TBL] [Abstract][Full Text] [Related]
8. Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
Chauffert B; Pelletier H; Corda C; Solary E; Bedenne L; Caillot D; Martin F
Br J Cancer; 1990 Sep; 62(3):395-7. PubMed ID: 2206948
[TBL] [Abstract][Full Text] [Related]
9. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
12. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
14. Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR.
Solary E; Velay I; Chauffert B; Caillot D; Bidan JM; Dumas M; Casasnovas O; Guy H
Nouv Rev Fr Hematol (1978); 1990; 32(5):361-3. PubMed ID: 2099412
[TBL] [Abstract][Full Text] [Related]
15. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
16. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
17. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
18. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
19. Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo.
Chauffert B; Martin M; Hammann A; Michel MF; Martin F
Cancer Res; 1986 Feb; 46(2):825-30. PubMed ID: 3940645
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
